NASDAQ · Stocky rates: Hold

EW

$88.97 ▼ -0.70% as of 5 Aug, 20:00
64
/ 100
Hold

What Stocky thinks

Hold. Edwards Lifesciences earns a middling Compounder Score (61/100) despite structural strengths in structural heart devices—a durable niche with high switching costs. Leadership alignment is solid (73.8/100), but the core vulnerability is financial: at 29.7× forward P/E with a Vulnerability Index of 100, valuation leaves minimal margin for execution stumbles. A quality business at a premium price.

Compounder Score
61/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
74/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
100/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
52/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for EW:

64
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 64/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

74
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

100
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

EW (EW) — frequently asked

Is EW (EW) a good investment right now?

Stocky rates EW (EW) at 64/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. Edwards Lifesciences earns a middling Compounder Score (61/100) despite structural strengths in structural heart devices—a durable niche with high switching costs. Leadership alignment is solid (73.8/100), but the core vulnerability i

What is EW's Stocky Verdict?

EW's current Stocky Verdict is 64/100, placing it in the "Hold" band. This composite combines a 61/100 Compounder score, 74/100 Leadership, Moat rating, and analyst signal.

Does EW have a competitive moat?

Stocky hasn't finalised a Moat Score for EW yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is EW's leadership aligned with shareholders?

EW scores 74/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to EW?

EW's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to EW.

This is just the surface. See the whole picture on EW.

Sign up free and unlock the full analysis on EW — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering EW — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for EW.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how EW changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to EW?" · "Is EW overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
64
/ 100 · Hold

Or jump straight to the interactive dashboard for EW in the app.